Comparative Pharmacology
Head-to-head clinical analysis: PREFRIN A versus VASOCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREFRIN A versus VASOCON A.
PREFRIN-A vs VASOCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Antazoline is an H1-receptor antagonist that blocks histamine-induced vasodilation and increased capillary permeability. Naphazoline is a direct-acting alpha-adrenergic agonist that constricts conjunctival blood vessels, reducing redness and swelling.
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
Adults: 1-2 drops in each nostril every 8-12 hours, not to exceed 2 doses per day. Do not use for more than 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Terminal elimination half-life: 6-8 hours; extends to 12-18 hours in hepatic impairment.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Renal excretion of unchanged drug: 60-80%; biliary/fecal: 20-40% as metabolites.
Category C
Category C
Ophthalmic Decongestant/Antihistamine Combination
Ophthalmic Decongestant/Antihistamine Combination